Which has better valuation & earnings, ATHA or CRBP?

Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$96.94M -$9.68 N/A Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A

Is ATHA or CRBP more profitable?

Corbus Pharmaceuticals' return on equity of -70.89% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -107.06% -89.89% Corbus Pharmaceuticals N/A -70.89% -61.78%

Does the media favor ATHA or CRBP?

In the previous week, Corbus Pharmaceuticals had 5 more articles in the media than Athira Pharma. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 beat Corbus Pharmaceuticals' score of -0.14 indicating that Athira Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, ATHA or HURA?

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$96.94M -$9.68 N/A TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A

Is ATHA or HURA more profitable?

Athira Pharma's return on equity of -107.06% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -107.06% -89.89% TuHURA Biosciences N/A -156.12% -105.38%

Does the media prefer ATHA or HURA?

In the previous week, TuHURA Biosciences had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for TuHURA Biosciences and 1 mentions for Athira Pharma. TuHURA Biosciences' average media sentiment score of 1.87 beat Athira Pharma's score of 0.00 indicating that TuHURA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TuHURA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, CRDL or ATHA?

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A Athira Pharma N/A N/A -$96.94M -$9.68 N/A

Is CRDL or ATHA more profitable?

Athira Pharma's return on equity of -107.06% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Athira Pharma N/A -107.06% -89.89%

Is ATHA or SPRB more profitable?

Athira Pharma's return on equity of -107.06% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -107.06% -89.89% Spruce Biosciences N/A -155.40% -101.67%

Does the media prefer ATHA or SPRB?

In the previous week, Spruce Biosciences had 2 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Spruce Biosciences and 1 mentions for Athira Pharma. Spruce Biosciences' average media sentiment score of 0.96 beat Athira Pharma's score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ATHA or ACOG?

In the previous week, Alpha Cognition had 2 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Alpha Cognition and 1 mentions for Athira Pharma. Alpha Cognition's average media sentiment score of 1.34 beat Athira Pharma's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Cognition 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Athira Pharma (ATHA) Competitors

$8.22 -0.39 (-4.53%)

As of 06/5/2026

Compare

ATHA vs. CRBP, HURA, CRDL, SPRB, and ACOG

Should you buy Athira Pharma stock or one of its competitors? MarketBeat compares Athira Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Athira Pharma include Corbus Pharmaceuticals (CRBP), TuHURA Biosciences (HURA), Cardiol Therapeutics (CRDL), Spruce Biosciences (SPRB), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry.

How does Athira Pharma compare to Corbus Pharmaceuticals?

Athira Pharma (NASDAQ:ATHA) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

Athira Pharma has a beta of 2.79, meaning that its share price is 179% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.57, meaning that its share price is 157% more volatile than the broader market.

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Corbus Pharmaceuticals had 5 more articles in the media than Athira Pharma. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 beat Corbus Pharmaceuticals' score of -0.14 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Athira Pharma presently has a consensus price target of $4.00, suggesting a potential downside of 51.34%. Corbus Pharmaceuticals has a consensus price target of $42.00, suggesting a potential upside of 412.82%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Corbus Pharmaceuticals' return on equity of -70.89% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

Summary

Corbus Pharmaceuticals beats Athira Pharma on 10 of the 14 factors compared between the two stocks.

How does Athira Pharma compare to TuHURA Biosciences?

Athira Pharma (NASDAQ:ATHA) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Athira Pharma's return on equity of -107.06% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
TuHURA Biosciences	N/A	-156.12%	-105.38%

Athira Pharma presently has a consensus target price of $4.00, suggesting a potential downside of 51.34%. TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 287.93%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe TuHURA Biosciences is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Athira Pharma has a beta of 2.79, indicating that its stock price is 179% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

In the previous week, TuHURA Biosciences had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for TuHURA Biosciences and 1 mentions for Athira Pharma. TuHURA Biosciences' average media sentiment score of 1.87 beat Athira Pharma's score of 0.00 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TuHURA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 19.8% of Athira Pharma shares are held by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

Summary

TuHURA Biosciences beats Athira Pharma on 7 of the 13 factors compared between the two stocks.

How does Athira Pharma compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 1 articles in the media. Cardiol Therapeutics' average media sentiment score of 1.89 beat Athira Pharma's score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardiol Therapeutics	Very Positive
Athira Pharma	Neutral

Cardiol Therapeutics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.79, suggesting that its stock price is 179% more volatile than the broader market.

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 19.8% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cardiol Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 725.24%. Athira Pharma has a consensus price target of $4.00, suggesting a potential downside of 51.34%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A

Athira Pharma's return on equity of -107.06% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Athira Pharma	N/A	-107.06%	-89.89%

Summary

Cardiol Therapeutics and Athira Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Athira Pharma compare to Spruce Biosciences?

Athira Pharma (NASDAQ:ATHA) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Athira Pharma's return on equity of -107.06% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
Spruce Biosciences	N/A	-155.40%	-101.67%

Athira Pharma has a beta of 2.79, suggesting that its stock price is 179% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.12, suggesting that its stock price is 212% more volatile than the broader market.

Athira Pharma presently has a consensus price target of $4.00, suggesting a potential downside of 51.34%. Spruce Biosciences has a consensus price target of $169.67, suggesting a potential upside of 226.97%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Spruce Biosciences has higher revenue and earnings than Athira Pharma. Spruce Biosciences is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
Spruce Biosciences	$4.91M	29.06	-$38.97M	-$36.60	N/A

In the previous week, Spruce Biosciences had 2 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Spruce Biosciences and 1 mentions for Athira Pharma. Spruce Biosciences' average media sentiment score of 0.96 beat Athira Pharma's score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spruce Biosciences beats Athira Pharma on 9 of the 14 factors compared between the two stocks.

How does Athira Pharma compare to Alpha Cognition?

Athira Pharma (NASDAQ:ATHA) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Athira Pharma has a beta of 2.79, suggesting that its stock price is 179% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.36, suggesting that its stock price is 136% more volatile than the broader market.

Athira Pharma presently has a consensus price target of $4.00, indicating a potential downside of 51.34%. Alpha Cognition has a consensus price target of $14.67, indicating a potential upside of 144.85%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts clearly believe Alpha Cognition is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Athira Pharma has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Alpha Cognition's return on equity of -58.35% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
Alpha Cognition	-232.23%	-58.35%	-45.99%

Alpha Cognition has higher revenue and earnings than Athira Pharma. Alpha Cognition is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
Alpha Cognition	$10.83M	12.05	-$20.67M	-$1.35	N/A

In the previous week, Alpha Cognition had 2 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Alpha Cognition and 1 mentions for Athira Pharma. Alpha Cognition's average media sentiment score of 1.34 beat Athira Pharma's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Cognition	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

57.1% of Athira Pharma shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by insiders. Comparatively, 14.0% of Alpha Cognition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Alpha Cognition beats Athira Pharma on 10 of the 15 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHA vs. The Competition

Export

Metric	Athira Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$32.42M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.85	20.00	24.00	24.42
Price / Sales	N/A	306.76	515.84	118.72
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.71	8.32	10.60	6.82
Net Income	-$96.94M	$23.94M	$3.57B	$337.56M
7 Day Performance	N/A	1.84%	0.59%	1.16%
1 Month Performance	-25.27%	-0.04%	1.54%	3.16%
1 Year Performance	170.39%	44.82%	25.41%	30.60%

Athira Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHA Athira Pharma	0.1284 of 5 stars	$8.22 -4.5%	$4.00 -51.3%	+170.4%	$32.42M	N/A	N/A	40
CRBP Corbus Pharmaceuticals	3.9924 of 5 stars	$7.54 -2.7%	$42.00 +457.0%	-7.2%	$143.59M	N/A	N/A	40
HURA TuHURA Biosciences	2.2612 of 5 stars	$2.18 -2.7%	$9.00 +312.8%	-5.7%	$142.65M	N/A	N/A	N/A
CRDL Cardiol Therapeutics	2.5662 of 5 stars	$1.15 -5.7%	$8.50 +639.1%	-29.5%	$140.60M	N/A	N/A	20
SPRB Spruce Biosciences	2.5943 of 5 stars	$49.30 -2.8%	$176.60 +258.2%	+826.2%	$139.54M	$4.91M	N/A	20	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athira Pharma (ATHA) Competitors

ATHA vs. CRBP, HURA, CRDL, SPRB, and ACOG

How does Athira Pharma compare to Corbus Pharmaceuticals?

Summary

How does Athira Pharma compare to TuHURA Biosciences?

Summary

How does Athira Pharma compare to Cardiol Therapeutics?

Summary

How does Athira Pharma compare to Spruce Biosciences?

Summary

How does Athira Pharma compare to Alpha Cognition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athira Pharma (ATHA) Competitors

ATHA vs. CRBP, HURA, CRDL, SPRB, and ACOG

How does Athira Pharma compare to Corbus Pharmaceuticals?

Which has better valuation & earnings, ATHA or CRBP?

Which has more volatility and risk, ATHA or CRBP?

Do insiders and institutionals hold more shares of ATHA or CRBP?

Does the media favor ATHA or CRBP?

Do analysts recommend ATHA or CRBP?

Is ATHA or CRBP more profitable?

Summary

How does Athira Pharma compare to TuHURA Biosciences?

Is ATHA or HURA more profitable?

Do analysts rate ATHA or HURA?

Which has more risk and volatility, ATHA or HURA?

Does the media prefer ATHA or HURA?

Do institutionals & insiders hold more shares of ATHA or HURA?

Which has better earnings & valuation, ATHA or HURA?

Summary

How does Athira Pharma compare to Cardiol Therapeutics?

Does the media refer more to CRDL or ATHA?

Which has more volatility and risk, CRDL or ATHA?

Do insiders & institutionals believe in CRDL or ATHA?

Do analysts rate CRDL or ATHA?

Which has stronger earnings and valuation, CRDL or ATHA?

Is CRDL or ATHA more profitable?

Summary

How does Athira Pharma compare to Spruce Biosciences?

Is ATHA or SPRB more profitable?

Which has more volatility and risk, ATHA or SPRB?

Do analysts prefer ATHA or SPRB?

Do institutionals & insiders hold more shares of ATHA or SPRB?

Which has preferable earnings & valuation, ATHA or SPRB?

Does the media prefer ATHA or SPRB?

Summary

How does Athira Pharma compare to Alpha Cognition?

Which has more risk & volatility, ATHA or ACOG?

Do analysts prefer ATHA or ACOG?

Is ATHA or ACOG more profitable?

Which has preferable valuation and earnings, ATHA or ACOG?

Does the media prefer ATHA or ACOG?

Do institutionals & insiders believe in ATHA or ACOG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools